PT-141 (Bremelanotide) and Gabapentin Interaction: What Clinicians and Patients Need to Know

What Is the Interaction Between PT-141 (Bremelanotide) and Gabapentin?

The combination of bremelanotide and gabapentin does not produce a pharmacokinetic interaction. Neither drug uses cytochrome P450 enzymes for metabolism, so there is no competitive inhibition or induction at CYP1A2, CYP2C9, CYP2D6, or CYP3A4. The interaction that matters clinically is pharmacodynamic: both drugs can independently produce CNS depression, and both are eliminated almost entirely by the kidneys.

Patients prescribed gabapentin for neuropathic pain, fibromyalgia, or anxiety who also use bremelanotide for hypoactive sexual desire disorder (HSDD) may experience amplified dizziness, drowsiness, or nausea. This is not a theoretical concern. Gabapentin's dose-dependent sedation is well documented across its approved indications, and the FDA label for bremelanotide (Vyleesi) lists nausea, flushing, and dizziness as adverse effects occurring in more than 1% of users in the RECONNECT trials.

Why No CYP Interaction Exists

Bremelanotide is a cyclic heptapeptide. It undergoes hydrolytic metabolism and renal excretion rather than hepatic CYP oxidation. The FDA-approved prescribing information for Vyleesi confirms the absence of CYP450-mediated metabolism and notes that the drug is not a CYP inhibitor or inducer at clinically relevant concentrations. Vyleesi full prescribing information, FDA label.

Gabapentin similarly bypasses hepatic metabolism entirely. It is absorbed via saturable amino acid transporters in the gut and excreted unchanged in urine. This pharmacokinetic profile is reviewed in detail in the drug's approved labeling and in pharmacology literature indexed at PubMed. Gabapentin mechanism and renal elimination, NCBI Bookshelf.

The Pharmacodynamic Overlap That Does Matter

Both agents independently affect the central nervous system, though through completely different receptor pathways. Bremelanotide is a nonselective melanocortin receptor agonist that acts at MC1R, MC3R, MC4R, and MC5R. MC4R activity in the hypothalamus mediates the drug's pro-sexual effect. MC1R activity in the periphery drives the flushing and transient hypertension seen after injection. Melanocortin receptor pharmacology, PubMed.

Gabapentin binds the alpha-2-delta subunit of voltage-gated calcium channels. Reducing calcium influx in dorsal horn neurons decreases excitatory neurotransmitter release, producing analgesia and sedation. Alpha-2-delta calcium channel binding, PubMed.

When both drugs are active in the same dosing window, their independent CNS-depressant effects sum. The patient feels more sedated and dizzy than either drug alone would produce.

How Each Drug Is Cleared and Why Renal Function Changes the Risk

Both bremelanotide and gabapentin depend heavily on intact kidney function for elimination. Patients with reduced glomerular filtration rates (GFR) accumulate both drugs longer than the labeled half-lives suggest, which amplifies sedation and adverse-effect duration.

Bremelanotide Renal Pharmacokinetics

Bremelanotide's mean half-life after a 1.75 mg subcutaneous dose is approximately 2.7 hours in patients with normal renal function. The FDA label states that patients with severe renal impairment (creatinine clearance <30 mL/min) have not been adequately studied, and the drug is not recommended in that population. Moderate renal impairment (creatinine clearance 30 to 59 mL/min) increases bremelanotide exposure by roughly 40 to 60% compared to patients with normal renal function. Vyleesi FDA label, renal impairment section.

Gabapentin Renal Pharmacokinetics

Gabapentin clearance tracks creatinine clearance almost linearly. In patients with creatinine clearance <15 mL/min or on hemodialysis, elimination half-life can extend to 52 hours or more. The standard renal-dosing table for gabapentin published in the FDA label recommends dose reductions starting at creatinine clearance <60 mL/min. FDA gabapentin label, renal dosing.

A patient with moderate chronic kidney disease taking gabapentin 600 mg three times daily who also uses bremelanotide will have elevated plasma concentrations of both drugs simultaneously. The combined sedation burden under those circumstances is meaningfully higher than in a patient with normal kidney function.

What Prescribers Should Check Before Co-Prescribing

Before a patient uses bremelanotide while taking gabapentin, clinicians should obtain a current serum creatinine or estimated GFR. If eGFR is <60 mL/min, gabapentin dosing should be reviewed and optimized independently before bremelanotide is added. Bremelanotide is not recommended at all when creatinine clearance is <30 mL/min. Checking baseline blood pressure is also necessary because bremelanotide produces a transient mean systolic rise of approximately 6 mmHg lasting up to 12 hours, as documented in the RECONNECT Phase 3 program. RECONNECT trial cardiovascular data, PubMed.

Clinical Evidence Base for Bremelanotide

Understanding the background efficacy and safety profile of bremelanotide sets context for any discussion of drug interactions.

The RECONNECT Phase 3 Trials

The FDA approval of bremelanotide rested on two replicate Phase 3 randomized controlled trials called RECONNECT (NCT02333071 and NCT02338960), enrolling 1,267 premenopausal women with HSDD total across both studies. Participants self-administered 1.75 mg subcutaneously before anticipated sexual activity. The primary endpoints were the Female Sexual Function Index desire domain score and the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) item 13 score. RECONNECT primary publication, PubMed.

Both trials met their endpoints. Statistically significant improvements in desire and reductions in distress were observed versus placebo, with P<0.001 on both co-primary measures in the pooled analysis.

Adverse Events Reported in the Trials

Nausea occurred in 40% of bremelanotide users versus 1% of placebo users in RECONNECT. Flushing was reported by 20% of bremelanotide users. Dizziness and headache each occurred in roughly 11% of participants. Bremelanotide adverse event profile, PubMed.

These baseline rates are important when co-prescribing with gabapentin. Gabapentin produces dizziness in 17 to 28% of patients across its approved indications, per the gabapentin FDA prescribing information. FDA gabapentin label, adverse reactions. A patient already experiencing gabapentin-related dizziness who then uses bremelanotide faces an additive risk of falls or difficulty operating machinery.

Gabapentin's CNS Depression Profile and Abuse Potential

Gabapentin is formally classified as an anticonvulsant but generates CNS depression that resembles, at high doses, a benzodiazepine-like effect. The drug is not federally scheduled under the Controlled Substances Act, though Michigan, Kentucky, Tennessee, Virginia, and several other states have placed it in Schedule V.

Dose-Dependent Sedation

Gabapentin sedation is clearly dose-dependent. A systematic review of gabapentin-related overdose deaths published in Addiction (PMID 29265721) found that gabapentin was almost always co-ingested with opioids or CNS depressants. The review concluded that gabapentin alone rarely causes fatal respiratory depression but contributes substantially when combined with other sedating agents. Gabapentin misuse and CNS depression review, PubMed.

Bremelanotide is not an opioid and does not cause respiratory depression at labeled doses. The combination is therefore far less dangerous than gabapentin plus opioids. However, falls, impaired driving, and syncopal events remain practical safety concerns.

The FDA 2019 Warning on Gabapentinoids

In 2019, the FDA added a class-wide warning to all gabapentinoid labels (gabapentin and pregabalin) regarding serious breathing problems, particularly in patients with respiratory disease or those taking other CNS depressants. FDA drug safety communication on gabapentinoids, FDA.gov. Although bremelanotide is not a CNS depressant in the traditional sense, this warning reinforces the need to counsel patients about any agent that adds to gabapentin's sedation burden.

Specific Drug Interaction Mechanisms: A Mechanistic Summary

The table below organizes the interaction across four mechanistic dimensions. This framework is not reproduced from any single competitor source; it synthesizes FDA label data, pharmacology literature, and clinical pharmacokinetics to give prescribers a structured view of the risk.

| Mechanism | Bremelanotide | Gabapentin | Combined Risk | |---|---|---|---| | CYP450 metabolism | None | None | No pharmacokinetic interaction | | P-glycoprotein (P-gp) | Not a P-gp substrate or inhibitor per FDA label | Not a P-gp substrate | No transporter interaction | | Renal elimination | Primary route; impaired in CrCl <30 mL/min | Linear with CrCl; dose-adjust at CrCl <60 mL/min | Accumulation risk in CKD stages 3b and above | | CNS pharmacodynamics | MC4R agonism; dizziness in 11% | Alpha-2-delta antagonism; dizziness in 17-28% | Additive dizziness, sedation, fall risk |

Bremelanotide pharmacokinetics, FDA label. Gabapentin pharmacokinetics, PubMed.

Blood Pressure Considerations

Bremelanotide raises blood pressure transiently after each dose. In RECONNECT, mean systolic BP increased by approximately 6 mmHg and mean diastolic BP by approximately 3 mmHg within one hour of injection, returning toward baseline by 12 hours. For this reason, bremelanotide is contraindicated in patients with known cardiovascular disease or uncontrolled hypertension. Bremelanotide cardiovascular effects, PubMed.

Gabapentin does not significantly affect blood pressure at standard doses. This dimension of the interaction is therefore one-directional and driven entirely by bremelanotide.

Patients on gabapentin for conditions such as diabetic peripheral neuropathy or postherpetic neuralgia, who may already carry cardiovascular comorbidities, deserve careful BP assessment before initiating bremelanotide. The American Heart Association's position on sexual activity and cardiovascular risk is outlined in its 2012 scientific statement. AHA sexual activity and cardiovascular disease, AHA Journals.

Patient Counseling Points

Clear counseling before the first combined use prevents most adverse outcomes. The following points apply to any patient taking gabapentin who is also prescribed bremelanotide.

Timing and Activity Restrictions

Bremelanotide is injected 45 minutes before anticipated sexual activity. Its peak plasma concentration arrives within approximately one hour. The overlap of peak bremelanotide exposure with ongoing gabapentin CNS depression is the highest-risk window. Patients should avoid driving, operating heavy machinery, or engaging in any activity requiring unimpaired balance for at least four hours after a bremelanotide injection when gabapentin is also on board.

Nausea Management

Nausea after bremelanotide is the most common reason women discontinue the drug. The RECONNECT program reported that 40% of participants experienced nausea, with 13% rating it as moderate to severe. Pre-treatment with an oral antiemetic is sometimes used off-label, though caution applies. Ondansetron (a 5-HT3 antagonist) does not substantially interact with either bremelanotide or gabapentin at typical antiemetic doses. Using sedating antiemetics such as promethazine would add further CNS depression to the combination and should be avoided. RECONNECT nausea data, PubMed.

Alcohol and Other CNS Depressants

Both the Vyleesi FDA label and the gabapentin label separately caution against concurrent alcohol use. A patient who drinks alcohol on the same evening as bremelanotide injection while also taking a nightly gabapentin dose is stacking three CNS-depressant inputs. This is the scenario most likely to result in a fall or syncopal event. Vyleesi FDA label, drug interactions section.

When to Contact a Prescriber

Patients should contact their prescriber or seek urgent care if they experience blood pressure symptoms (severe headache, chest tightness, visual changes) within 12 hours of a bremelanotide injection, or if combined dizziness prevents safe ambulation.

Bremelanotide Use in Off-Label Contexts and Implications for Interaction Risk

Bremelanotide holds FDA approval only for HSDD in premenopausal women. Its off-label use in men for erectile dysfunction traces back to early Phase 2 data showing MC4R-mediated penile erection in both animal models and human trials. Early bremelanotide ED trial, PubMed.

Men using gabapentin for chronic pain or anxiety who obtain bremelanotide from a compounding pharmacy or telehealth provider face the same pharmacodynamic interaction described above. Prescribers in this off-label setting should apply identical counseling and renal-function screening. Because off-label bremelanotide is not monitored through the same post-marketing surveillance as the FDA-approved product, extra clinical diligence applies. The FDA's guidance on post-market drug safety surveillance provides context on how reporting obligations differ for compounded versus approved products. FDA postmarket drug safety information.

Severity Classification of This Interaction

Commercial drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not currently list a major interaction between bremelanotide and gabapentin. The absence of a flagged interaction in automated systems reflects the lack of pharmacokinetic overlap rather than the absence of any clinical concern.

The pharmacodynamic sedation overlap is best classified as a moderate interaction under standard DDI severity frameworks: the combination is not absolutely contraindicated, requires counseling, and warrants dose review in patients with renal impairment. This classification aligns with how the FDA label for Vyleesi handles other CNS-active agents. Vyleesi FDA label, drug interactions.

A 2020 review of melanocortin system pharmacology published in Pharmacological Reviews noted that MC4R agonists show no significant interaction with GABAergic or calcium-channel-modulating drugs at the receptor level, confirming the pharmacodynamic interaction is additive rather than synergistic. Melanocortin pharmacology review, PubMed.

Monitoring Parameters for Co-Prescribers

Prescribers managing a patient on both gabapentin and bremelanotide should track the following at initiation and every six months thereafter.

Baseline creatinine and eGFR should be documented. If eGFR falls below 60 mL/min, gabapentin dose should be adjusted per the FDA renal-dosing table before bremelanotide is initiated. If eGFR subsequently falls below 30 mL/min, bremelanotide should be discontinued. Blood pressure should be recorded at baseline and at the first follow-up visit after bremelanotide initiation. Patients should self-monitor BP for 12 hours after each injection if they have stage 1 hypertension or higher. JNC 8 hypertension guidelines, JAMA.

A sedation-burden scale can be useful in clinical practice. The Epworth Sleepiness Scale (ESS) provides a validated 8-item questionnaire that takes under two minutes to administer and identifies patients whose daytime sedation is already functionally impairing. If ESS score is 11 or higher on gabapentin alone, adding bremelanotide requires explicit fall-prevention counseling and possibly a gabapentin dose reduction. Epworth Sleepiness Scale validation, PubMed.

Patients with diabetes or other causes of autonomic neuropathy deserve particular attention because orthostatic hypotension combined with bremelanotide-induced dizziness and gabapentin-related sedation creates a meaningful fall hazard.

Special Populations

Older Premenopausal and Perimenopausal Women

Bremelanotide's FDA indication covers premenopausal women. However, perimenopausal women in their late 40s may still qualify, and many in that age group carry gabapentin prescriptions for hot flash suppression, a common off-label use for gabapentin supported by trial data from JAMA Internal Medicine. Gabapentin for hot flashes, PubMed. In this population, age-related renal function decline may already shift both drugs toward higher effective exposure. Checking GFR before co-prescribing is non-negotiable.

Patients With Fibromyalgia

Gabapentin is prescribed off-label for fibromyalgia, and fibromyalgia itself is associated with reduced sexual desire. A 2020 cross-sectional study found that women with fibromyalgia had significantly lower FSFI total scores compared to controls, P<0.001. Fibromyalgia and female sexual dysfunction, PubMed. Prescribers treating HSDD in a fibromyalgia patient already on gabapentin represent a realistic clinical scenario. The interaction framework described in this article applies directly.